# US 2004/0018561 A1 · Peptide compounds and their use as protease substrates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018561 A1
- Document ID: US20040018561A1
- Status: Published application
- Kind: A1
- Application number: 10/435,486
- Filed: 2003-05-10
- Published: 2004-01-29
- Earliest claimed: 2002-05-10
- Inventors: Gary A. DeCrescenzo; Carol P. Howard; Joseph G. Rico; Kun Zhang
- Web page: https://patentgrep.com/patent/US20040018561A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12Q 1/37: involving peptidase or proteinase
- C12Q 2337/00: N-linked chromogens for determinations of peptidases and proteinases
- G01N 2333/96486: Metalloendopeptidases (3.4.24)
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention is directed generally to peptide compounds and salts, and particularly to peptide compounds and salts that are useful as protease substrates, such as matrix metalloprotease (“MMP”) substrates. This invention also is directed to methods for making such compounds and salts, as well as amino acids that may, for example, be used in such methods. This invention is further directed to methods for using such compounds and salts to, for example, evaluate the effectiveness of potential protease inhibitors and to detect or monitor a disease associated with protease activity.

## Claims

### Claim 1

A compound or a salt thereof, wherein:
the compound comprises a peptide and corresponds in structure to Formula (I):
aa(i)-X—Y-aa(j)-Z (I);
aa(i) comprises a sequence of i amino acids at the N-terminus of the peptide;
aa(j) comprises a sequence of j amino acids at the C-terminus of the peptide;
i is an integer from 0 to 5;
j is an integer from 1 to 6;
a fluorophore is covalently attached to the peptide on one side of the X—Y bond, and at least one of a fluorescence quencher and a ligand is covalently attached to the peptide on the other side of the X—Y bond;
X comprises an MMP recognition sequence;
X is not Pro-Gln-Gln, Pro-Tyr-Ala, or Pro-Val-Glu;
Y comprises an amino acid; and
Z is:
a hydroxyl group at the C-terminus of the peptide, or
a protecting group at the C-terminus of the peptide.

### Claim 2 (depends on 1)

A compound or salt thereof according to claim 1, wherein Y comprises a side chain comprising at least 8 non-hydrogen atoms.

### Claim 3 (depends on 2)

A compound or salt thereof according to claim 2, wherein Y comprises a side chain comprising at least 10 non-hydrogen atoms.

### Claim 4 (depends on 3)

A compound or salt thereof according to claim 3, wherein Y comprises a side chain comprising at least 11 non-hydrogen atoms.

### Claim 5 (depends on 4)

A compound or salt thereof according to claim 4, wherein Y comprises a side chain comprising from 11 to 15 non-hydrogen atoms.

### Claim 6 (depends on 4)

A compound or salt thereof according to claim 4, wherein Y comprises a side chain comprising at least 12 non-hydrogen atoms.

### Claim 7 (depends on 1)

A compound or salt thereof according to claim 1, wherein the compound or salt is characterized in that MMP-2, MMP-9, or MMP-13 reacts with the compound or salt to cleave the compound or salt at the bond between X and Y when the compound or salt is combined with the MMP-2, MMP-9, or MMP-13.

### Claim 8 (depends on 7)

A compound or salt thereof according to claim 7, wherein:
kcat/Km of the compound or salt with at least one of MMP-1 and MMP-7 is no greater than about 0.5×10−4M−1s−1, and
kcat/Km of the compound or salt with at least one of MMP-2, MMP-9, and MMP-13 is at least about 5×10−4M−1s−1.

### Claim 9 (depends on 8)

A compound or salt thereof according to claim 8, wherein:
kcat/Km of the compound or salt with at least one of MMP-1 and MMP-7 is no greater than about 10−5 M−1s−1, and
kcat/Km of the compound or salt with at least one of MMP-2, MMP-9, and MMP-13 is at least about 50×10−4M−1s−1.

### Claim 10 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt is characterized in that the rate of reaction of the compound or salt with MMP-1 or MMP-7 is about zero.

### Claim 11 (depends on 10)

A compound or salt thereof according to claim 10, wherein the compound or salt is characterized in that the rate of reaction of the compound or salt with MMP-1 and MMP-7 is about zero.

### Claim 12 (depends on 7)

A compound or salt thereof according to claim 7, wherein Y is selected from the group consisting of 3-(2-napthyl)-L-alanine, O-benzyl-L-tyrosine, 6-(benzyloxy)-L-norleucine, S-(3-phenylpropyl)-L-cysteine, 6-phenoxy-L-norleucine and S-(4-methoxybenzyl)-L-cysteine.

### Claim 13 (depends on 7)

A compound or salt thereof according to claim 7, wherein Y is selected from the group consisting of 6-(benzyloxy)-L-norleucine and 6-phenoxy-L-norleucine.

### Claim 14 (depends on 7)

A compound or salt thereof according to claim 7, wherein the recognition sequence of X is selected from the group consisting of Ala-Gln-Gly, Ala-Met-His, Asn-Gln-Gly, Asp-Lys-Glu, Dnp-Gln-Gly, Dnp-Leu-Gly, Ile-Gly-Phe, Lys-Pro-Asn, Pro-Arg-Gly, Pro-Asp-Gly, Pro-Gln -Tyr, Pro-Gln-Ala, Pro-Gln-Glu, Pro-Gln-Gly, Pro-Gln-His, Pro-Gln-Leu, Pro-Gln-Met, Pro-Gln-Phe, Pro-Gln-Pro, Pro-Gln-Val, Pro-Glu-Asn, Pro-Glu-Gly, Pro-His-Gly, Pro-Leu-Ala, Pro-Leu-Gly, Pro-Met-Gly, Pro-Tyr-Gly, Pro-Val-Ala, Pro-Ser-Glu-Asn, Ser-Gly-Asn, Ser-His-Ser, Ser-Ile-Pro, Thr-Glu-Lys, Tyr-Arg-Trp, Tyr-His-Ser, and Pro-Leu-MeCys.

### Claim 15 (depends on 7)

A compound or salt thereof according to claim 7, wherein Y comprises a side chain comprising at least 8 non-hydrogen atoms.

### Claim 16 (depends on 15)

A compound or salt thereof according to claim 15, wherein Y comprises a side chain comprising 11 non-hydrogen atoms.

### Claim 17 (depends on 16)

A compound or salt thereof according to claim 16, wherein the side chain corresponds in structure to Formula (17-1):
73

### Claim 18 (depends on 16)

A compound or salt thereof according to claim 16, wherein the side chain corresponds in structure to Formula (18-1):
74

### Claim 19 (depends on 16)

A compound or salt thereof according to claim 16, wherein the side chain corresponds in structure to Formula (19-1):
75

### Claim 20 (depends on 16)

A compound or salt thereof according to claim 16, wherein the side chain corresponds in structure to Formula (20-1):
76

### Claim 21 (depends on 15)

A compound or salt thereof according to claim 15, wherein Y comprises a side chain comprising at least 12 non-hydrogen atoms.

### Claim 22 (depends on 21)

A compound or salt thereof according to claim 21, wherein the side chain corresponds in structure to Formula (22-1):
77

### Claim 23 (depends on 22)

A compound or salt thereof according to claim 22, wherein the compound corresponds in structure to Formula (23-1):
78

### Claim 24 (depends on 22)

A compound or salt thereof according to claim 22, wherein the compound corresponds in structure to Formula (24-1):
79

### Claim 25 (depends on 15)

A compound or salt thereof according to claim 15, wherein Y comprises a side chain comprising 15 non-hydrogen atoms.

### Claim 26 (depends on 25)

A compound or salt thereof according to claim 25, wherein the side chain corresponds in structure to Formula (26-1):
80

### Claim 27 (depends on 7)

A compound or salt thereof according to claim 7, wherein i is zero.

### Claim 28 (depends on 7)

A compound or salt thereof according to claim 7, wherein i is 1.

### Claim 29 (depends on 7)

A compound or salt thereof according to claim 7, wherein j is from 3 to 5.

### Claim 30 (depends on 29)

A compound or salt thereof according to claim 29, wherein i is zero or 1.

### Claim 31 (depends on 7)

A compound or salt thereof according to claim 7, wherein aa(i) or aa(j) comprises an amino acid selected from the group consisting of arginine, lysine, aspartic acid, and glutamic acid.

### Claim 32 (depends on 31)

A compound or salt thereof according to claim 31, wherein:
aa(i) comprises an amino acid selected from the group consisting of arginine, lysine, aspartic acid, and glutamic acid; and
aa(j) comprises an amino acid selected from the group consisting of arginine, lysine, aspartic acid, and glutamic acid.

### Claim 33 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt has a water solubility that is greater than a Km of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, MMP-14, or MMP-26.

### Claim 34 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt has a water solubility of at least about 20 μM in 1% DMSO at pH 7.5.

### Claim 35 (depends on 34)

A compound or salt thereof according to claim 34, wherein the compound or salt has a water solubility of at least about 100 μM in 1% DMSO at pH 7.5.

### Claim 36 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt comprises at least one amino acid having a log D contribution of less than about zero.

### Claim 37 (depends on 7)

A compound or salt thereof according to claim 7, wherein the amino acid having a log D contribution of less than about zero is selected from the group consisting of D-Arginine, L-Arginine, D-Asparagine, L-Asparagine, D-Glutamic Acid, L-Glutamic acid, D-Histidine, L-Histidine, D-Glutamine, L-Glutamine, D-Lysine, L-Lysine, D-Serine, L-Serine, D-Threonine, L-Threonine, Glycine, D-Alanine, L-Alanine, D-citrulline, L-citrulline, D-ornithine, and L-ornithine.

### Claim 38 (depends on 7)

A compound or salt thereof according to claim 7, wherein the fluorophore is a coumarin.

### Claim 39 (depends on 38)

A compound or salt thereof according to claim 38, wherein the coumarin is substituted N-2-[(7-methoxy-2-oxo-2H-chromen-4-yl)acetyl].

### Claim 40 (depends on 38)

A compound or salt thereof according to claim 38, wherein the coumarin is N-2-[(7-methoxy-2-oxo-2H-chromen-4-yl)acetyl].

### Claim 41 (depends on 7)

A compound or salt thereof according to claim 7, wherein the fluorophore is a fluorescein.

### Claim 42 (depends on 41)

A compound or salt thereof according to claim 41, wherein the fluorescein is substituted N-6-(4-{[3-carboxy-4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl]amino}-6-chloro-1,3,5-triazin-2-yl).

### Claim 43 (depends on 41)

A compound or salt thereof according to claim 41, wherein the fluorescein is N-6-(4-{[3-carboxy-4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl]amino}-6-chloro-1,3,5-triazin-2-yl).

### Claim 44 (depends on 7)

A compound or salt thereof according to claim 7, wherein a fluorophore is covalently attached to the peptide on one side of the X—Y bond, and a fluorescence quencher is covalently attached to the peptide on the other side of the X—Y bond.

### Claim 45 (depends on 44)

A compound or salt thereof according to claim 44, wherein the fluorescence quencher is substituted (2,4-dinitrophenyl)amino.

### Claim 46 (depends on 44)

A compound or salt thereof according to claim 44, wherein the fluorescence quencher is (2,4-dinitrophenyl)amino.

### Claim 47 (depends on 7)

A compound or salt thereof according to claim 7, wherein a fluorophore is covalently attached to the peptide on one side of the X—Y bond, and a ligand is covalently attached to the peptide on the other side of the X—Y bond.

### Claim 48 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is bound non-covalently to a solid support.

### Claim 49 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is substituted biotin.

### Claim 50 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is biotin.

### Claim 51 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is substituted N-2-[(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl].

### Claim 52 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is N-2-[(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl].

### Claim 53 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is substituted epsilon amino caproic acid.

### Claim 54 (depends on 47)

A compound or salt thereof according to claim 47, wherein the ligand is epsilon amino caproic acid.

### Claim 55 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt comprises at least one D-amino acid.

### Claim 56 (depends on 7)

A compound or salt thereof according to claim 7, wherein the compound or salt comprises at least one amino acid selected from the group consisting of a beta-amino acid and a gamma-amino acid.

### Claim 57 (depends on 7)

A compound or salt thereof according to claim 7, wherein Z is a protecting group.

### Claim 58 (depends on 57)

A compound or salt thereof according to claim 57, wherein Z is an optionally-substituted amine.

### Claim 59 (depends on 1)

A compound or salt thereof according to claim 1, wherein the compound corresponds in structure to a formula selected from group consisting of:
81 82 83 84 85 86 87 88 89 90

### Claim 60 (depends on 1)

A compound or salt thereof according to claim 1, wherein the compound is selected from the group consisting of, SEQ ID NO: 8, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25.

### Claim 61

A compound or a salt thereof, wherein:
the compound comprises a peptide and corresponds in structure to Formula (I):
aa(i)-X—Y-aa(j)-Z (I);
aa(i) comprises a sequence of i amino acids at the N-terminus of the peptide;
aa(j) comprises a sequence of j amino acids at the C-terminus of the peptide;
the peptide comprises a D-amino acid;
i is an integer from 0 to 5;
j is an integer from 1 to 6;
a fluorophore is covalently attached to the peptide on one side of the X—Y bond, and at least one of a fluorescence quencher and a ligand is covalently attached to the peptide on the other side of the X—Y bond;
X comprises an MMP recognition sequence;
Y comprises a bond or amino acid; and
Z is:
a hydroxyl group at the C-terminus of the peptide, or
a protecting group at the C-terminus of the peptide.

### Claim 62 (depends on 61)

A compound or salt thereof according to claim 61, wherein the recognition sequence of X is selected from the group consisting of Ala-Gln-Gly, Ala-Met-His, Asn-Gln-Gly, Asp-Lys-Glu, Dnp-Gln-Gly, Dnp-Leu-Gly, Ile-Gly-Phe, Lys-Pro-Asn, Pro-Arg-Gly, Pro-Asp-Gly, Pro-Gln -Tyr, Pro-Gln-Ala, Pro-Gln-Gln, Pro-Gln-Glu, Pro-Gln-Gly, Pro-Gln-His, Pro-Gln-Leu, Pro-Gln-Met, Pro-Gln-Phe, Pro-Gln-Pro, Pro-Gln-Val, Pro-Glu-Asn, Pro-Glu-Gly, Pro-His-Gly, Pro-Leu-Ala, Pro-Leu-Gly, Pro-Met-Gly, Pro-Tyr-Ala, Pro-Tyr-Gly, Pro-Val-Ala, Pro-Val-Glu, Pro-Ser-Glu-Asn, Ser-Gly-Asn, Ser-His-Ser, Ser-Ile-Pro, Thr-Glu-Lys, Tyr-Arg-Trp, Tyr-His-Ser, and Pro-Leu-MeCys.

### Claim 63 (depends on 61)

A compound or salt thereof according to claim 61, wherein the compound corresponds in structure to a formula selected from group consisting of:
91 92 93 94 95

### Claim 64

A compound or a salt thereof, wherein:
the compound comprises a peptide, and
the peptide comprises an amino acid selected from the group consisting of phenyloxynorleucine and benzyloxynorleucine.

### Claim 65 (depends on 64)

A compound or salt thereof according to claim 64, wherein the compound or salt is characterized in that MMP-2, MMP-9, or MMP-13 reacts with the compound or salt to cleave the compound or salt at a bond between two amino acids when the compound or salt is combined with the MMP-2, MMP-9, or MMP-13.

### Claim 66 (depends on 65)

A compound or salt thereof according to claim 65, wherein the compound or salt comprises phenyloxynorleucine.

### Claim 67 (depends on 66)

A compound or salt thereof according to claim 66, wherein the compound or salt is characterized in that MMP-2, MMP-9, or MMP-13 reacts with the compound or salt to cleave the compound or salt at a bond between the phenyloxynorleucine and another amino acid when the compound or salt is combined with the MMP-2, MMP-9, or MMP-13.

### Claim 68 (depends on 66)

A compound or salt thereof according to claim 66, wherein the compound corresponds in structure to Formula (68-1):
96

### Claim 69 (depends on 65)

A compound or salt thereof according to claim 65, wherein the compound or salt comprises benzyloxynorleucine.

### Claim 70 (depends on 69)

A compound or salt thereof according to claim 69, wherein the compound or salt is characterized in that MMP-2, MMP-9, or MMP-13 reacts with the compound or salt to cleave the compound or salt at a bond between the benzyloxynorleucine and another amino acid when the compound or salt is combined with the MMP-2, MMP-9, or MMP-13.

### Claim 71 (depends on 69)

A compound or salt thereof according to claim 69, wherein the compound corresponds in structure to a formula selected from group consisting of:
97 98 99

### Claim 72 (depends on 1)

A method for determining the activity of a matrix metalloprotease, wherein the method comprises combining the matrix metalloprotease with a compound or salt recited in claim 1.

### Claim 73 (depends on 59, 72)

A method according to claim 72, wherein the compound or salt is a compound or salt recited in claim 59.

### Claim 74 (depends on 72)

A method according to claim 72, wherein the matrix metalloprotease is MMP-2.

### Claim 75 (depends on 72)

A method according to claim 72, wherein the matrix metalloprotease is MMP-9.

### Claim 76 (depends on 72)

A method according to claim 72, wherein the matrix metalloprotease is MMP-13.

### Claim 77 (depends on 1, 72)

A method according to claim 72, wherein the method comprises combining:
one or more of MMP-2, MMP-9, and MMP-13;
one or more of MMP-1 and MMP-7; and
the compound or salt recited in claim 1.

### Claim 78 (depends on 1)

A method for ex-vivo detection or monitoring of a disease associated with a pathological matrix metalloprotease level, wherein the method comprises measuring a cleavage of a compound or salt recited in claim 1 at the bond between X and Y.

### Claim 79 (depends on 59, 78)

A method according to claim 78, wherein the compound or salt is a compound or salt recited in claim 59.

### Claim 80 (depends on 78)

A method according to claim 78, wherein the matrix metalloprotease is MMP-2.

### Claim 81 (depends on 78)

A method according to claim 78, wherein the matrix metalloprotease is MMP-9.

### Claim 82 (depends on 78)

A method according to claim 78, wherein the matrix metalloprotease is MMP-13.

### Claim 83 (depends on 1)

A method for determining the activity of a matrix metalloprotease in a biological sample, wherein the method comprises:
combining the biological sample with a compound or salt recited in claim 1 to form a mixture, and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 84 (depends on 59, 83)

A method according to claim 83, wherein the compound or salt is a compound or salt recited in claim 59.

### Claim 85 (depends on 83)

A method according to claim 83, wherein the matrix metalloprotease is MMP-2.

### Claim 86 (depends on 83)

A method according to claim 83, wherein the matrix metalloprotease is MMP-9.

### Claim 87 (depends on 83)

A method according to claim 83, wherein the matrix metalloprotease is MMP-13.

### Claim 88 (depends on 1)

A method for measuring inhibitory activity of a prospective inhibitor of a matrix metalloprotease, wherein the method comprises:
combining the following to form a mixture:
a compound or salt recited in claim 1,
the prospective inhibitor, and
the matrix metalloprotease; and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 89 (depends on 59, 88)

A method according to claim 88, wherein the compound or salt is a compound or salt recited in claim 59.

### Claim 90 (depends on 88)

A method according to claim 88, wherein the matrix metalloprotease is MMP-2.

### Claim 91 (depends on 88)

A method according to claim 88, wherein the matrix metalloprotease is MMP-9.

### Claim 92 (depends on 88)

A method according to claim 88, wherein the matrix metalloprotease is MMP-13.

### Claim 93 (depends on 61)

A method for determining the activity of a matrix metalloprotease, wherein the method comprises combining the matrix metalloprotease with a compound or salt recited in claim 61.

### Claim 94 (depends on 63, 93)

A method according to claim 93, wherein the compound or salt is a compound or salt recited in claim 63.

### Claim 95 (depends on 93)

A method according to claim 93, wherein the matrix metalloprotease is MMP-2.

### Claim 96 (depends on 93)

A method according to claim 93, wherein the matrix metalloprotease is MMP-9.

### Claim 97 (depends on 93)

A method according to claim 93, wherein the matrix metalloprotease is MMP-13.

### Claim 98 (depends on 61, 93)

A method according to claim 93, wherein the method comprises combining:
one or more of MMP-2, MMP-9, and MMP-13;
one or more of MMP-1 or MMP-7; and
the compound or salt recited in claim 61.

### Claim 99 (depends on 61)

A method for ex-vivo detection or monitoring of a disease associated with a pathological matrix metalloprotease level, wherein the method comprises measuring a cleavage of a compound or salt recited in claim 61 at the bond between X and Y.

### Claim 100 (depends on 63, 99)

A method according to claim 99, wherein the compound or salt is a compound or salt recited in claim 63.

### Claim 101 (depends on 99)

A method according to claim 99, wherein the matrix metalloprotease is MMP-2.

### Claim 102 (depends on 99)

A method according to claim 99, wherein the matrix metalloprotease is MMP-9.

### Claim 103 (depends on 99)

A method according to claim 99, wherein the matrix metalloprotease is MMP-13.

### Claim 104 (depends on 61)

A method for determining the activity of a matrix metalloprotease in a biological sample, wherein the method comprises:
combining the biological sample with a compound or salt recited in claim 61 to form a mixture, and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 105 (depends on 63, 104)

A method according to claim 104, wherein the compound or salt is a compound or salt recited in claim 63.

### Claim 106 (depends on 104)

A method according to claim 104, wherein the matrix metalloprotease is MMP-2.

### Claim 107 (depends on 104)

A method according to claim 104, wherein the matrix metalloprotease is MMP-9.

### Claim 108 (depends on 104)

A method according to claim 104, wherein the matrix metalloprotease is MMP-13.

### Claim 109 (depends on 61)

A method for measuring inhibitory activity of a prospective inhibitor of a matrix metalloprotease, wherein the method comprises:
combining the following to form a mixture:
a compound or salt recited in claim 61,
the prospective inhibitor, and
the matrix metalloprotease; and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 110 (depends on 63, 109)

A method according to claim 109, wherein the compound or salt is a compound or salt recited in claim 63.

### Claim 111 (depends on 109)

A method according to claim 109, wherein the matrix metalloprotease is MMP-2.

### Claim 112 (depends on 109)

A method according to claim 109, wherein the matrix metalloprotease is MMP-9.

### Claim 113 (depends on 109)

A method according to claim 109, wherein the matrix metalloprotease is MMP-13.

### Claim 114 (depends on 64)

A method for determining the activity of a matrix metalloprotease, wherein the method comprises combining the matrix metalloprotease with a compound or salt recited in claim 64.

### Claim 115 (depends on 68, 71, 114)

A method according to claim 114, wherein the compound or salt is a compound or salt recited in claim 68 or 71.

### Claim 116 (depends on 114)

A method according to claim 114, wherein the matrix metalloprotease is MMP-2.

### Claim 117 (depends on 114)

A method according to claim 114, wherein the matrix metalloprotease is MMP-9.

### Claim 118 (depends on 114)

A method according to claim 114, wherein the matrix metalloprotease is MMP-13.

### Claim 119 (depends on 64, 114)

A method according to claim 114, wherein the method comprises combining:
one or more of MMP-2, MMP-9, and MMP-13;
one or more of MMP-1 and MMP-7; and
the compound or salt recited in claim 64.

### Claim 120 (depends on 64)

A method for ex-vivo detection or monitoring of a disease associated with a pathological matrix metalloprotease level, wherein the method comprises measuring a cleavage of a compound or salt recited in claim 64.

### Claim 121 (depends on 68, 71, 120)

A method according to claim 120, wherein the compound or salt is a compound or salt recited in claim 68 or 71.

### Claim 122 (depends on 120)

A method according to claim 120, wherein the matrix metalloprotease is MMP-2.

### Claim 123 (depends on 120)

A method according to claim 120, wherein the matrix metalloprotease is MMP-9.

### Claim 124 (depends on 123)

A method according to claim 123, wherein the disease is an eye disease.

### Claim 125 (depends on 124)

A method according to claim 124, wherein the disease is glaucoma.

### Claim 126 (depends on 124)

A method according to claim 124, wherein the disease is selected from the group consisting of macular degeneration and diabetic macular edema.

### Claim 127 (depends on 120)

A method according to claim 120, wherein the matrix metalloprotease is MMP-13.

### Claim 128 (depends on 64)

A method for determining the activity of a matrix metalloprotease in a biological sample, wherein the method comprises:
combining the biological sample with a compound or salt recited in claim 64 to form a mixture, and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 129 (depends on 68, 71, 128)

A method according to claim 128, wherein the compound or salt is a compound or salt recited in claim 68 or 71.

### Claim 130 (depends on 128)

A method according to claim 128, wherein the matrix metalloprotease is MMP-2.

### Claim 131 (depends on 128)

A method according to claim 128, wherein the matrix metalloprotease is MMP-9.

### Claim 132 (depends on 131)

A method according to claim 131, wherein the biological sample comprises a fluid or tissue from an eye.

### Claim 133 (depends on 128)

A method according to claim 128, wherein the matrix metalloprotease is MMP-13.

### Claim 134 (depends on 64)

A method for measuring inhibitory activity of a prospective inhibitor of a matrix metalloprotease, wherein the method comprises:
combining the following to form a mixture:
a compound or salt recited in claim 64,
the prospective inhibitor, and
the matrix metalloprotease; and
analyzing the mixture for the presence of a reaction product of the compound or salt with the matrix metalloprotease.

### Claim 135 (depends on 68, 71, 134)

A method according to claim 134, wherein the compound or salt is a compound or salt recited in claim 68 or 71.

### Claim 136 (depends on 134)

A method according to claim 134, wherein the matrix metalloprotease is MMP-2.

### Claim 137 (depends on 134)

A method according to claim 134, wherein the matrix metalloprotease is MMP-9.

### Claim 138 (depends on 134)

A method according to claim 134, wherein the matrix metalloprotease is MMP-13.

### Claim 139 (depends on 1)

A kit for detecting or monitoring a disease associated with pathological activity of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 1.

### Claim 140 (depends on 59, 139)

A kit according to claim 139, wherein the compound or salt is a compound or salt recited in claim 59.

### Claim 141 (depends on 61)

A kit for detecting or monitoring a disease associated with pathological activity of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 61.

### Claim 142 (depends on 63, 141)

A kit according to claim 141, wherein the compound or salt is a compound or salt recited in claim 63.

### Claim 143 (depends on 64)

A kit for detecting or monitoring a disease associated with pathological activity of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 64.

### Claim 144 (depends on 68, 71, 143)

A kit according to claim 143, wherein the compound or salt is a compound or salt recited in claim 68 or 71.

### Claim 145 (depends on 1)

A kit for evaluating the effectiveness of a prospective inhibitor of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 1.

### Claim 146 (depends on 61)

A kit for evaluating the effectiveness of a prospective inhibitor of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 61.

### Claim 147 (depends on 64)

A kit for evaluating the effectiveness of a prospective inhibitor of a matrix metalloprotease, wherein the kit comprises a compound or salt recited in claim 64.

### Claim 148

A compound or a salt thereof, wherein:
the compound corresponds in structure to Formula (II):
100
n is zero or 1, and
R1 and R2 are independently selected from the group consisting of hydrogen and a nitrogen protecting group.

### Claim 149 (depends on 148)

A compound or salt thereof according to claim 148, wherein the compound corresponds in structure to Formula (IIA):
101

### Claim 150 (depends on 149)

A compound or salt thereof according to claim 149, wherein the compound corresponds in structure to a formula selected from the group consisting of:
102
